PrefHer研究最终分析:HER2阳性早期乳腺癌辅助治疗中皮下与静脉曲妥珠单抗的疗效与安全性
PrefHer研究纳入488例HER2阳性早期乳腺癌患者,随机接受皮下曲妥珠单抗(固定剂量600 mg)与静脉曲妥珠单抗(负荷8 mg/kg、维持6 mg/kg)交替方案辅助治疗。中位随访36.1个月,可评估意向治疗人群(467例)3年无事件生存率总体为90.6%,队列1为89.9%,队列2为91.1%。长期随访未发现新的安全性信号,安全性人群(483例)中仅发生1例心脏严重不良事件。
要点
- 皮下与静脉曲妥珠单抗交替辅助治疗3年EFS总体90.6%。
- 队列1(单次注射装置皮下)3年EFS为89.9%,队列2(手持注射器皮下)为91.1%。
- 长期随访未发现新安全性信号,安全性人群仅1例心脏严重不良事件。
核心结论
- 皮下与静脉曲妥珠单抗辅助治疗的3年EFS数据与既往辅助治疗试验报告一致。
- 辅助治疗期间总体安全性特征符合预期。
研究设计与样本
- 随机、两队列PrefHer研究(NCT01401166),共随机488例患者。
- 入组为HER2阳性早期乳腺癌术后、化疗后(新)辅助治疗患者。
- 随机接受4周期皮下曲妥珠单抗(600 mg固定剂量;队列1单次注射装置,队列2手持注射器从药瓶抽取)后4周期静脉曲妥珠单抗(负荷8 mg/kg、维持6 mg/kg),或相反顺序,每3周一次。
- 随机前可已接受曲妥珠单抗,继续治疗至总共18周期(含随机前周期)。
- 可评估意向治疗人群467例,安全性人群483例。
主要发现
- 中位随访36.1个月,可评估意向治疗人群3年EFS总体为90.6%。
- 队列1的3年EFS为89.9%,队列2的3年EFS为91.1%。
- 长期随访未发现新的安全性信号。
- 安全性人群中仅发生1例心脏严重不良事件。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166). PATIENTS AND METHODS: Post surgery and post chemotherapy in the (neo)adjuvant setting, patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer were randomised to receive four cycles of the subcutaneous form of trastuzumab (Herceptin® SC [H SC] via single-use injection device [Cohort 1] or delivery via a hand-held syringe from an SC Vial [Cohort 2]; 600 mg fixed dose) followed by four of the intravenous form of trastuzumab (Herceptin® [H IV]; 8 mg/kg loading, 6 mg/kg maintenance doses) in the adjuvant setting or vice versa every 3 weeks. Patients could have received H before randomisation. H was then continued to complete a total of 18 cycles, including any cycles received before randomisation. RESULTS: A total of 488 patients were randomised across both cohorts. After median follow-up of 36.1 months, 3-year EFS across both groups in the evaluable intention-to-treat population (467 patients) was 90.6% overall, 89.9% in Cohort 1, and 91.1% in Cohort 2. No new safety signals were identified during long-term follow-up, with only one cardiac serious adverse event in the safety population (483 patients). CONCLUSIONS: Three-year EFS data following H SC and H IV treatment are consistent with those reported by previous trials for H in the adjuvant setting. The overall safety profile during adjuvant treatment was as expected.
引用
- Pivot X, Verma S, Fallowfield L, et al. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer. 2017. PMID: 28963915. doi:10.1016/j.ejca.2017.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。